Publications by authors named "P Harter"

Claim this Profile
A
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Philipp Harter, Frederik Marmé, Andrés Redondo, Alexander Reuss, Kristina Lindemann

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification.
Martin Sill, Daniel Schrimpf, Areeba Patel, Dominik Sturm, Natalie Jäger, Patrick N Harter

Cancer Cell· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
P Harter, F Trillsch, A Okamoto, A Reuss, J-W Kim

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Dale Garsed, Tibor Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Philipp Harter

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis.
Ji Hyun Kim, Myong Cheol Lim, Eun Taeg Kim, Uisuk Kim, Sholanki Halder, Philipp Harter

Int J Gynecol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis